GNCA - Genocea to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.
Conferences:
| Event: |
| Longwood Healthcare Leaders Winter Webconference - Details |
| Topic 1: |
| Innovation in Cell Therapy |
| Format: |
| Panel |
| Date: |
| Thursday, January 6, 2022 |
| Time: |
| 1:30 PM ET |
| Topic 2: |
| Making a Big Impact With Limited Resources |
| Format: Date: Time: |
| Panel Thursday, January 6, 2022 5:10 PM ET |
Event: |
LifeSci Partners 11 th Annual Corporate Access Event - Details |
| Topic 1: |
| Innovative Approaches to Cell Therapy for Oncology |
| Format: |
| Panel |
| Date: |
| Friday, January 7, 2022 |
| Time: |
| 8:30 AM ET |
| Topic 2: |
| Cancer Vaccines: Promises, Promises … Has Their Day Come? |
| Format: Date: Time: |
| Panel Friday, January 7, 2022 2:00 PM ET |
| Event: |
| H.C. Wainwright BIOCONNECT Virtual Conference - Details |
| Topic: |
| Corporate Update |
| Format: |
| On demand presentation |
| Date: |
| Monday, January 10, 2022 |
| Time: |
| 7:00 AM ET |
| Event: |
| Advanced Therapies Week - Details |
| Topic: |
| Add It Up: 3 Things to Consider for Capacity Expansion |
| Format: |
| Panel |
| Date: |
| Wednesday, January 26, 2022 |
| Time: |
| 5:00 PM ET |
About Genocea Biosciences, Inc.
Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens TM , that drive pro-tumor immune responses. We have two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our adoptive T cell therapy comprising neoantigen-targeted peripheral cells for which we are conducting a Phase 1/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit https://www.genocea.com .
| Investor Contact: |
| Media Contact: |
| Dan Ferry |
| Sarah O’Connell |
| 617-430-7576 |
| soconnell@vergescientific.com |
| daniel@lifesciadvisors.com |